Skip to main content
Top of the Page

SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to expedite worldwide research and education through the exchange of scientific information.

Learn more »

SOHO represents physicians and other professionals from all corners of the world. SOHO is leading vital efforts to further treatments for those with hematologic malignancies. Become a SOHO Member free-of-charge. Join us and experience the benefits of membership.

Join Now

The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. Note that SOHO members receive a 40% discount on registration fees. We expect approximately 3,000 hematologic oncology specialists to participate in the upcoming Eleventh Annual Meeting of the Society (SOHO 2023). Click for more information and registration.

Register now
  • 7,453 members strong

Join Us Today and Become a Part of the SOHO Community

Benefits of membership include:
  • Instant connections to our SOHO Community of more than 6,000 members
  • Access to a comprehensive Resource Center that includes slides, publications, abstracts, videos & more
  • Connection to our SOHO DocMatter Community for hematologic oncology discussions and education
  • Free online access to our official journal, ‘Clinical Lymphoma Myeloma and Leukemia
  • Free online and print subscription (US members) to our news publication, 'Blood Cancers Today'
  • Significant member-only discounts on meetings and events
  • Early member-only registration and housing opportunities
  • ... and much more!

Ambassador Program

The Ambassador Program was created to increase geographical diversity and promote international understanding among hematologic oncology experts around the world. If you are interested, Contact us!

Latest News

Can Novel Targeted Therapies Improve Outcomes for CRLF2-Rearranged B-ALL?

The median OS for the patients receiving targeted therapy was 11.8 months, while it was 5.8 months for the patients receiving conventional chemotherapy.

Study Suggests Link Between Aging, Low-Hypodiploid ALL

The proportion of low-hypodiploid ALL within Ph-negative B-cell ALL “dramatically increased with age.”

Researchers Uncover Mechanisms of BH3 Mimetic Resistance in T-cell ALL

Investigators studied mechanisms of resistance to BH3 mimetics to “develop rational combination strategies" for the treatment of T-cell ALL

Luspatercept Improved Anemia, Transfusion Burden in Myelofibrosis

The open-label ACE-536-MF-001 study evaluated luspatercept in cohorts of patients grouped by transfusion-dependance and ruxolitinib treatment status.

First-Line Selinexor, Ruxolitinib Shows Ongoing Promise for Myelofibrosis

Updated data from the phase I XPORT-MF-034 trial of selinexor plus ruxolitinib showed rapid, deep, and sustained spleen responses in patients with myelofibrosis.

Pacritinib Spleen Response Yielded OS Benefit in Cytopenic Myelofibrosis

Spleen volume reduction was associated with a significant OS benefit in patients with myelofibrosis who had low platelets and received pacritinib.

Dr. Garcia-Manero on the Data Behind the Luspatercept Approval

Guillermo Garcia-Manero, MD, reflects on the phase III COMMANDS trial, the recent approval of luspatercept, and other developments in MDS

"Very interesting and exciting to share ideas and data with other hem/onc clinicians and scientists from around the world"
–Prof. Dieter Hoelzer, founding member
Back to Top